DB18672InvestigationalGene Therapies
Suratadenoturev is a gene-modified oncolytic adenovirus expressing the telomerase reverse transcriptase gene.
- Also known as
- A recombinant replication-competent adenovirus type 5 (Ad-5) in which the E1 gene, including its normal transcriptional regulatory element, has been deleted and replaced by an expression cassette containing an hTERT (human telomerase reverse transcriptas · A replication-competent adenovirus type 5 in which the E1A and E1B genes are under the control of a human telomerase reverse transcriptase (hTERT) and IRES, respectively. · DNA (recombinant human telomerase-specific replication-competent oncolytic adenovirus 5 vector OBP-301) · Telomelysin · Telomerase Specific Replication-competent Oncolytic Adenovirus
- Code names
- OBP-301
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Suratadenoturev, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account